Appendix I: References for included and cited studies

1 Anon (2001) The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6 American Journal of Ophthalmology 132 (5) 668-681


3 Ahmadieh H, Taei R, Riazi-Esfahani M et al. (2011) Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial Retina 31 1819-1826


6 Amoaku WM, Chakravarthy U, Gale R et al. (2015) Defining response to anti-VEGF therapies in neovascular AMD Eye 29 (6) 721-731

7 Arias L, Armada F, Donate J et al. (2009) Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss Eye 23 (2) 326-333


11 Bartlett HE, Eperjesi F (2007) Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial European journal of clinical nutrition 61 (9) 1121-1127

12 Bashshur ZF, Schakal AR, El-Mollyess GM et al. (2011) Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration Retina (Philadelphia, Pa.) 31 636-644

13 Batioglu F, Demirel S, Ozmert E et al. (2015) Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD BMC ophthalmol 15 40-

1 Berg K, Pedersen TR, Sandvik L et al. (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol Ophthalmology 122 (1) 146-152
4 Biswas P, Sengupta S, Choudhary R et al. (2011) Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration Indian journal of ophthalmology 59 (3) 191-
5 Bittner AK, Torr-Brown S, Arnold E et al. (2014) Improved Adherence to Vision Self-monitoring with the Vision and Memory Stimulating (VMS) Journal for Non-neovascular Age-related Macular Degeneration during a Randomized Controlled Trial Journal of clinical & experimental ophthalmology 5 (1) 320-
7 Boulanger-Scemama E, Querques G, About F et al. (2015) Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting Journal Francais d Opthalmologie 38 620-627
8 Brader HS, Ying GS, Martin ER et al. (2011) New grading criteria allow for earlier detection of geographic atrophy in clinical trials Investigative ophthalmology & visual science 52 (12) 9218-9225
9 Bressler SB, Maguire MG, Bressler NM et al. (1990) Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group Archives of ophthalmology (Chicago, Ill.: 1960) 1442-1447
12 Brody BL, Roch-Levecq AC, Thomas RG et al. (2005) Self-management of age-related macular degeneration at the 6-month follow-up: a randomized controlled trial Archives of Ophthalmology 123 (1) 46-53


5 Buckle M, Donachie PH, Johnston RL (2016) Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK British Journal of Ophthalmology 100 (2) 240-245


7 Burton AE, Shaw RL, Gibson JM (2013) 'I'd like to know what causes it, you know, anything I've done?' Are we meeting the information and support needs of patients with macular degeneration? A qualitative study BMJ Open 3 (11) e003306


9 Busbee BG, Ho AC, Brown DM et al. (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 (5) 1046-1056

10 Bussija L, Pausenberger E, Haines TP et al. (2011) Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36 Item (SF 36) and Short Form 12 Item (SF12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF 6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQOL) Arthritis care & research 63 (S11) S383-S412


13 Cachulo L, Silva R, Fonseca P et al. (2010) Early markers of choroidal neovascularization in the fellow eye of patients with unilateral exudative age-related macular degeneration Ophthalmologica 225 (3) 144-149


15 Chakravarthy U, Wong TY, Fletcher A et al. (2010) Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis BMC ophthalmology 10 (1) 31-
1. Chakravarthy U, Harding SP, Rogers CA et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119 (7) 1399-1411

2. Chakravarthy U, Harding SP, Rogers CA et al. (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet 382 (9900) 1258-1267

3. Chakravarthy U, Harding SP, Rogers CA et al. (2015) A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)


5. Chang AA, Li H, Broadhead GK et al. (2013) Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. 41 52-


7. Chasan JE, Delaune B, Maa AY et al. (2014) Effect of a teleretinal screening program on eye care use and resources. JAMA Ophthalmology 132 (9) 1045-1051


Appendix I: References for included and cited studies


Appendix I: References for included and cited studies

1. Dakin HA, Wordsworth S, Rogers CA et al. (2014) Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial BMJ Open 4 (7) e005094-

2. Danis RP, Domalpally A, Chew EY et al. (2013) Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2) Investigative ophthalmology & visual science 54 (7) 4548-4554


1 El-Mollayess GM, Mahfoud Z, Schakal AR et al. (2013) Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity Retina 33 (9) 1828-1835


3 Eldem BM, Muftuoglu G, Topbas S et al. (2015) A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD Acta Ophthalmologica 93 (6) e458-e464


5 Elshout M, van der Reis MI, Webers CA et al. (2012) A new epidemiological aid in deciding whether to continue or stop a treatment Invest Ophthalmol Vis Sci 53 4331-4336

6 Elshout M, van der Reis MI, Webers CA et al. (2014) The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters Graefe's archive for clinical and experimental ophthalmology 252 (12) 1911-1920


8 Eter N, Spaide RF (2005) Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy Retina 25 (6) 691-696

9 Evans JR, Lawrenson JG (2012) Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration The Cochrane Library

10 Fang K, Tian J, Qing X et al. (2013) Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration Journal of ophthalmology 2013 676049-


12 Figueroa MS, Regueras A, Bertrand J (1994) Laser photocoagulation to treat macular soft drusen in age-related macular degeneration Retina 14 (5) 391-396


14 Fleiss JL (1971) Measuring nominal scale agreement among many raters Psychological bulletin 76 (5) 378-


3 Friberg TR, Brennen PM, Freeman WR (2009) Prophylactic treatment of age-related macular degeneration report number 2: 810-nanometer laser to eyes with drusen: bilaterally eligible patients Ophthalmic Surgery, Lasers & Imaging Retina 40 (6) 530-


7 Gerding H (2015) Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment Klinische Monatsblatter fur Augenheilkunde 232 (4) 560-563

8 Gharbiya M, Iannetti L, Parisi F et al. (2014) Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration Biomed Res Int 2014 273754-


10 Ghosh W, Wickstead R, Claxton L et al. (2016) The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK Advances in therapy 33 (9) 1660-1676

11 Giani A, Luiselli C, Esmaili DD et al. (2011) Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization Investigative ophthalmology & visual science 52 (8) 5579-5586

12 Gillespie BW, Musch DC, Niziol LM et al. (2014) Estimating Minimally Important Differences for Two Vision-Specific Quality of Life MeasuresMinimally Important Difference for NEI-VFQ and VAQ Investigative ophthalmology & visual science 55 (7) 4206-4212

13 Gillies MC, Campain A, Barthelmes D et al. (2015) Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study Ophthalmology 122 (9) 1837-1845


16 Goudie C, Lunt D, Reid S et al. (2014) Ophthalmic digital image transfer: benefits to triage, patient care and resource Ophthalmic & Physiological Optics 34 (6) 628-635

Griffin DR, Richmond PP, Olson JC (2014) Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration J Ophthalmol 2014 497178-

Grunwald JE, Daniel E, Huang J et al. (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials Ophthalmology 150-161

Guymer RH, Baird PN, Varsamidis M et al. (2013) Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration PLoS One 8 (12) e83759-


Hahn P, Acquah K, Cousins SW et al. (2013) Ten-year incidence of age-related macular degeneration according to diabetic retinopathy classification among medicare beneficiaries Retina (Philadelphia, Pa.)Retina 911-919


Hatz K, Schneider U, Henrich PB et al. (2015) Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study Ophthalmologica 233 66-73

Heier JS, Boyer D, Nguyen QD et al. (2011) The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing Ophthalmology 118 (6) 1098-1106


Hirneiss C (2014) The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life Clinical ophthalmology (Auckland, NZ) 8 1703-


Homer N, Grewal DS, Mirza RG et al. (2015) Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results Eye 29 1152-1155
2 Howard KP, Klein Barbara EK, Lee KE et al. (2014) Measures of body shape and adiposity as related to incidence of age-related eye diseases: observations from the Beaver Dam Eye Study Investigative ophthalmology &; visual scienceInvest Ophthalmol Vis Sci 2592-2598
3 Huang YM, Dou HL, Huang FF et al. (2015) Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial British Journal of Ophthalmology 99 (3) 371-375
5 Jaeschke R, Guyatt GH, Sackett DL et al. (1994) Users' Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test B. What Are the Results and Will They Help Me in Caring for My Patients? JAMA 271 (9) 703-707
9 Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension Graefe's Archive for Clinical and Experimental Ophthalmology 244 (9) 1132-1142
12 Kaltenthaler E, Tappenden P, Paisley S et al. (2011) NICE DSU technical support document 13: identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models Sheffield: Decision Support Unit, ScHARR, University of Sheffield
15 Khurana RN, Dupas B, Bressler NM (2010) Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization Ophthalmology 117 (7) 1376-1380


7. Klein R, Meuer SM, Myers CE et al. (2014) Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium Ophthalmic epidemiology 21 (1) 14-23


1 ranibizumab in patients with neovascular age-related macular degeneration Retina 33 1605-1612
2 Kuppermann BD, Goldstein M, Maturi RK et al. (2015) Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial Ophthalmologica 234 40-54
4 Lawrenson JG, Evans JR (2015) Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration The Cochrane Library
6 Lechanteur Yara TE, van d, V, Johannes PH et al. (2012) Genetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration Investigative ophthalmology & visual scienceInvest Ophthalmol Vis Sci 5846-5852
7 Li B, Powell AM, Hooper PL et al. (2015) Prospective evaluation of teleophthalmology in screening and recurrence monitoring of neovascular age-related macular degeneration: a randomized clinical trial JAMA Ophthalmology 133 (3) 276-282
11 Lim JI, Labree L, Nichols T et al. (2002) Comparison of nonmydriatic digitized video fundus images with standard 35-mm slides to screen for and identify specific lesions of age-related macular degeneration Retina 22 (1) 59-64
13 Lushchyk T, Amarakoon S, Martinez-Ciriano J et al. (2013) Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks Acta ophthalmologica 91 (6) e456-e461
16 Maguire MG, Bressler SB, Bresskr NM et al. (1997) Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal
neovascularization secondary to age-related macular degeneration Archives of Ophthalmology 115 (6) 741-747

Maguire MG, Ying GS, McCannel CA et al. (2009) Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial Ophthalmology 116 (12) 2381-2385


Mantel I, Gianniou C, Dirani A (2016) Conversion to Aflibercept Therapy Versus Continuing with Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration Dependent on Monthly Ranibizumab Treatment Retina 36 53-58


Mccloud C, Khadka J, Gilhotra JS et al. (2014) Divergence in the lived experience of people with macular degeneration Optometry & Vision Science 91 966-974


Menon G, Chandran M, Sivaprasad S et al. (2013) Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab&quest;(BEMOc Trial) Eye 27 (8) 959-963


7. Muether PS, Hermann MM, Koch K et al. (2011) Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity Graefes Archive for Clinical & Experimental Ophthalmology 249 (5) 633-637


Macular Degeneration
Appendix I: References for included and cited studies


15. Padnick-Silver L, Weinberg AB, Lafranco FP et al. (2012) Pilot study for the detection of early exudative age-related macular degeneration with optical coherence tomography Retina 32 (6) 1045-1056


Patel KH, Chow CC, Rathod R et al. (2013) Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye 27 663-667.

Perlee LT, Bansal AT, Gehrs K et al. (2013) Inclusion of genotype with fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic atrophy. Ophthalmology 120 (9) 1880-1892.


3 Reynolds R, Rosner B, Seddon JM (2013) Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy Ophthalmology 1020-1028


6 Rofagha S, Bhisitkul RB, Boyer DS et al. (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 (11) 2292-2299


9 Rovner BW, Casten RJ, Hegel MT et al. (2007) Preventing depression in age-related macular degeneration Archives of General Psychiatry 64 (8) 886-892

10 Rovner BW, Casten RJ, Hegel MT et al. (2013) Improving function in age-related macular degeneration: a randomized clinical trial Ophthalmology 120 (8) 1649-1655

11 Rovner BW, Casten RJ, Hegel MT et al. (2014) Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial Ophthalmology 121 (11) 2204-2211


13 Saito M, Kano M, Itagaki K et al. (2014) Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab Retina 34 2192-2201

14 Saito M, Kano M, Itagaki K et al. (2016) Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection Jpn J Ophthalmol 60 35-41


16 Sallet G, Lafaut BA, De Laey JJ (1996) Indocyanine green angiography and age-related serous pigment epithelial detachment Graefe’s archive for clinical and experimental ophthalmology 234 (1) 25-33

1. Sandhu SS, Talks SJ (2005) Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes British Journal of Ophthalmology 89 (8) 967-970

2. Sarao V, Parravano M, Veritti D et al. (2016) Intravitreal Aflibercept for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Ranibizumab Therapy Retina 36 (4) 770-777


7. Schmier JK, Halpern MT, Covert D et al. (2006) Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration Retina 26 (9) 1056-1062


10. Seddon JM, Cote J, Davis N et al. (2003) Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio Archives of ophthalmology (Chicago, Ill.: 1960) 785-792


Appendix I: References for included and cited studies


3. Shea BJ, Grimshaw JM, Wells GA et al. (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews BMC medical research methodology 7 (1) 10-

4. Shiragami C, Ono A, Kobayashi M et al. (2014) Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration 93 no-

5. Simcock P, Kingett B, Mann N et al. (2014) A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners Eye (Basingstoke) 28 (10) 1161-1164


7. Smith HJ, Dickinson CM, Cacho I et al. (2005) A randomized controlled trial to determine the effectiveness of prism spectacles for patients with age-related macular degeneration Archives of Ophthalmology 123 (8) 1042-1050


10. Stein JD, VanderBeek BL, Talwar N et al. (2011) Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups Investigative ophthalmology & visual scienceInvest Ophthalmol Vis Sci 6842-6848


1 Sullivan PW, Slejko JF, Sculpher MJ et al. (2011) Catalogue of EQ-5D scores for the United Kingdom Medical Decision Making 31 (6) 800-804
2 Sunness JS, Gonzalez-Baron J, Applegate CA et al. (1999) Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration Ophthalmology 106 (9) 1768-1779
3 Takahashi H, Ohkubo Y, Sato A et al. (2015) Relationship between visual prognosis and delay of intravitreal injection of ranibizumab when treating age-related macular degeneration Retina 35 (7) 1331-1338
7 Tappenden P, Chilcott J, Brennan A et al. (2013) Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model Value in Health 16 (4) 542-553
8 The Royal College of Ophthalmologists (2013) age-related macular degeneration: guidelines for management. London:
9 Thompson AC, Thompson MO, Young DL et al. (2015) Barriers to Follow-Up and Strategies to Improve Adherence to Appointments for Care of Chronic Eye Diseases Investigative ophthalmology & visual science 56 4324-4331
10 Thorell MR, Nunes RP, Chen GW et al. (2014) Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD Ophthalmic Surg Lasers Imaging Retina 45 526-533
11 Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report 1 Archives of Ophthalmology 117 (10) 1329-
13 Tufail A, Patel PJ, Egan C et al. (2010) Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study Bmj 340 c2459-
1 Van DM, A, Sandhu SS et al. (2006) Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes British Journal of Ophthalmology 90 (3) 304-306


3 van LR, Boekhoorn S, Vingerling JR et al. (2005) Dietary intake of antioxidants and risk of age-related macular degeneration JAMA 3101-3107

4 van V, M E, de S et al. (2006) Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT Graefes Archive for Clinical & Experimental Ophthalmology 244 (9) 1119-1123


6 Varano M, Eter N, Winyard S et al. (2015) Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey Clinical Ophthalmology 9 2243-2250

7 Vaze A, Fraser-Bell S, Gillies M (2014) Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration Retina 34 1774-1778

8 Verteporfin In Photodynamic Therapy Study (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization"verteporfin in photodynamic therapy report 2 American Journal of Ophthalmology 131 (5) 541-560

9 Virgili G, Michelessi M, Parodi MB et al. (2015) Laser treatment of drusen to prevent progression to advanced age-related macular degeneration The Cochrane Library

10 Visudyne in Minimally Classic Choroidal Neovascularization Study Group (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial Archives of Ophthalmology 123 (4) 448-

11 Vogel RN, Davis DB, Kimura BH et al. (2016) Neovascular age-related macular degeneration with advanced visual loss treated with anti-vascular endothelial growth factor therapy: Clinical Outcome and Prognostic Indicators Retina no-

12 Vottonen P, Kankaanp E (2016) Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model Acta ophthalmologica 94 (7) 652-656

13 Vukicevic M, Fitzmaurice K (2005) Rehabilitation strategies used to ameliorate the impact of centre field loss Visual Impairment Research 7 79-84


15 Vukicevic M, Heraghty J, Cummins R et al. (2016) Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration Eye 30 (3) 413-421


4. Williams PT (2009) Prospective study of incident age-related macular degeneration in relation to vigorous physical activity during a 7-year follow-up Investigative ophthalmology & visual science

5. Williams TA, Blyth CP (2011) Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12 Eye 25 (12) 1617-1621


15. Ying GS, Huang J, Maguire MG et al. (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 (1) 122-129

4 Yuzawa M, Fujita K, Wittrup-Jensen K et al. (2015) Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration Ophthalmology 122 (3) 571-578
